Copyright
©The Author(s) 2021.
World J Gastroenterol. Feb 7, 2021; 27(5): 428-441
Published online Feb 7, 2021. doi: 10.3748/wjg.v27.i5.428
Published online Feb 7, 2021. doi: 10.3748/wjg.v27.i5.428
Table 2 The primary endpoint of bowel cleansing efficacy as assessed by the Aronchick Scale (per-protocol analysis set)
| Quiklean®, n = 208 | Klean-Prep/Dulcolax®, n = 209 | P value | |
| Responses | |||
| Successful (Excellent + Good) | 205 | 204 | |
| Unsuccessful (Fair + Poor + Inadequate) | 3 | 5 | |
| Success rate | 98.6% | 97.6% | |
| Between-group difference | 0.95% | ||
| 95% exact CI | (-8.620%, 10.525%) | ||
| Rating, n (%) | |||
| Excellent | 50 (24.0) | 69 (33.0) | 0.1355 |
| Good | 155 (74.5) | 135 (64.6) | |
| Fair | 3 (1.4) | 4 (1.9) | |
| Poor | 0 | 1 (0.5) | |
| Inadequate | 0 | 0 | |
- Citation: Hung SY, Chen HC, Ke TW, Chen JH, Hsiao KH, Wang HM, Chiang HC, Chang SC, Chen YC, Hsieh MH, Tsai YY, Hsieh YW, Chen WTL. Noninferiority clinical trial comparing the bowel cleansing efficacy of sodium phosphate tablets (Quiklean®) with a polyethylene glycol/bisacodyl kit. World J Gastroenterol 2021; 27(5): 428-441
- URL: https://www.wjgnet.com/1007-9327/full/v27/i5/428.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i5.428